Kintor Pharmaceutical Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNTPF research report →
Companywww.kintor.com.cn
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours.
- CEO
- Youzhi Tong
- IPO
- 2020
- Employees
- 168
- HQ
- Suzhou, CN
Price Chart
Valuation
- Market Cap
- $164.41M
- P/E
- -5.46
- P/S
- 33.37
- P/B
- 5.88
- EV/EBITDA
- -8.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 24.60%
- Op Margin
- -611.29%
- Net Margin
- -601.18%
- ROE
- -98.57%
- ROIC
- -65.90%
Growth & Income
- Revenue
- $31.84M · 536.77%
- Net Income
- $-194,943,066 · -25.53%
- EPS
- $-0.43 · -19.44%
- Op Income
- $-197,355,170
- FCF YoY
- 15.08%
Performance & Tape
- 52W High
- $0.57
- 52W Low
- $0.18
- 50D MA
- $0.38
- 200D MA
- $0.31
- Beta
- -0.52
- Avg Volume
- 224
Get TickerSpark's AI analysis on KNTPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our KNTPF Coverage
We haven't published any research on KNTPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KNTPF Report →